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ABSTRACT 
The present manuscript describe simple, sensitive, rapid, accurate, precise and economical first derivative spectrophotometric method for the 
simultaneous determination of diazepam and propranolol hydrochloride in combined tablet dosage form. The derivative spectrophotometric 
method was based on the determination of both the drugs at their respective zero crossing point (ZCP). The first order derivative spectra was 
obtained in 0.05M methanolic sulphuric acid and the determinations were made at 248 nm (ZCP of propranolol hydrochloride) for diazepam 
and 242 nm (ZCP of diazepam) for propranolol hydrochloride. The linearity was obtained in the concentration range of 2.5-30 μg/ml for both 
diazepam  and  propranolol  hydrochloride.  The  mean  recovery  was  99.77  ±  1.39  and  100.6  ±  1.18  %  for  diazepam  and  propranolol 
hydrochloride, respectively. The method was found to be simple, sensitive, accurate and precise and was applicable for the simultaneous 
determination of diazepam and propranolol hydrochloride in pharmaceutical tablet dosage form. The results of analysis have been validated 
statistically and by recovery studies.   
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INTRODUCTION
    
Diazepam (DZP) is chemically 7-chloro-1, 3-dihydro-1-
methyl-5-phenyl-1,  4-  benzodiazepin-2-one; 
C16H13ClN2O
1, used as an anxiolytic agent
2. It is official 
in IP, USP and BP. IP
3 and BP
4 describes non-aqueous 
titration  method  and  USP
5  describe  liquid 
chromatography  method  for  its  estimation.  Literature 
survey  reveals  spectrophotometric
6-9, 
spectrofluorimetric
10,  GC
11,  HPLC
12,  HPTLC
13-14, 
LC/MS
15  and  radioimmunoassay
16  methods  for  the 
estimation  of  DZP  in  single  dosage  form.  Propranolol 
hydrochloride  (PRO)  is  chemically  (RS)-1-
isopropylamino-3-  (1-naphthyloxy)  propan-2-ol 
hydrochloride;  C16H21NO2,  HCl
17,  is  beta-adrenoceptor 
antagonist
18. The combination of DZP and PRO has been 
shown  to  be  effective  in  the  management  of  chronic 
anxiety. The combination
 was generally more effective 
than diazepam
18. Propranolol hydrochloride is official in 
IP, USP and BP. IP
19 and BP
20 describes potentiometric 
titration  method  and  USP
21  describe  liquid 
chromatography  method  for  its  estimation.  Literature 
survey  reveals  spectrophotometric
22-24,  fluorimetric
25, 
HPLC
26-27  and  chemiluminescence
28  methods  for 
estimation of propranolol hydrochloride in single dosage 
form.  This  combination  is  not  official  in  any 
pharmacopoeia, so no official method is available for the 
estimation of these two drugs in combined dosage forms. 
Literature  survey  reveals  spectrophotometric
29  method 
for  the  simultaneous  estimation  of  DZP  and  PRO  in 
combined dosage form. The present manuscript describes 
simple, sensitive, accurate, precise, rapid and economic 
first  order  derivative  spectrophotometric  method  for 
simultaneous determination of diazepam and propranolol 
hydrochloride in pharmaceutical tablet dosage form.  
MATERIALS AND METHODS 
Apparatus 
A  shimadzu  model  1700  (Japan)  double  beam 
UV/Visible spectrophotometer with spectral width of 2 
nm, wavelength accuracy of 0.5 nm and a pair of 10 mm 
matched quartz cell was used to measure absorbance of 
all the solutions. Spectra were automatically obtained by 
UV-Probe  system  software.  A  Sartorius  CP224S 
analytical  balance  (Gottingen,  Germany),  an  ultrasonic 
bath (Frontline  FS 4, Mumbai, India) was used  in the 
study.  
Reagents and Materials 
DZP  and  PRO  bulk  powder  was  kindly  gifted  by 
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India. The commercial fixed dose combination product 
containing  2  mg  DZP  and  10  mg  PRO  was  procured 
from the local pharmacy. Methanol and sulphuric acid, 
AR Grade was procured from S. D. Fine Chemicals Ltd., 
Mumbai, India.  
Preparation of standard stock solutions 
An  accurately  weighed  quantity  of  DZP  (10  mg)  and 
PRO  (10  mg)  were  transferred  to  a  separate  100  ml 
volumetric flask and dissolved and diluted to the mark 
with 0.05M methanolic sulphuric acid to obtain standard 
solution having concentration of DZP (100 μg/ml) and 
PRO (100 μg/ml).  
Methodology 
The standard solutions of DZP (10 µg/ml) and PRO (10 
µg/ml) were scanned separately in the UV range of 200-
400 nm. The zero-order spectra thus obtained was then 
processed  to  obtain  first-derivative  spectra.  Data  were 
recorded at an interval of 2 nm. The two spectra were 
overlain and it appeared that DZP showed zero crossing 
at 242 nm, while PRO showed zero crossing at 248 nm. 
At the zero crossing point (ZCP) of DZP (242 nm), PRO 
showed a first-derivative absorbance, whereas at the ZCP 
of  PRO  (248  nm),  DZP  showed  a  first-derivative 
absorbance.  Hence  248  and  242  nm  was  selected  as 
analytical  wavelengths  for  determination  of  DZP  and 
PRO,  respectively.  These  two  wavelengths  can  be 
employed  for  the  determination  of  DZP  and  PRO 
without  any  interference  from  the  other  drug  in  their 
combined dosage formulations.  
Validation of the proposed method 
 The  proposed  method  was  validated  according  to  the 
International  Conference  on  Harmonization  (ICH) 
guidelines
30. 
Linearity (Calibration curve) 
The calibration curves were plotted over a concentration 
range  of  2.5-30  μg/ml  for  each  DZP  and  PRO. 
Accurately  measured  standard  solutions  of  DZP  and 
PRO  (0.25,  0.5,  1.0,  1.5,  2.0,  2.5  and  3.0  ml)  were 
transferred  to  a  series  of  10  ml  of  volumetric  flasks, 
separately  and  diluted  to  the  mark  with  0.05M 
methanolic  sulphuric  acid,  and  first-derivative 
absorbances (D1) were measured at 248 nm for DZP and 
242  nm  for  PRO.  The  calibration  curves  were 
constructed  by  plotting  absorbances  versus 
concentrations  and  the  regression  equations  were 
calculated.        
Method precision (repeatability) 
The precision of the instrument was checked by repeated 
scanning and measurement of absorbance of solution (n 
= 6) for DZP and PRO (10 µg/ml) without changing the 
parameter  of  the  first-derivative  spectrophotometry 
method. 
Intermediate precision (reproducibility) 
The  intraday  and  interday  precision  of  the  proposed 
method was determined by analyzing the corresponding 
responses 3 times on the same day and on 3 different 
days  over  a  period  of  1  week  for  3  different 
concentrations of standard solutions of DZP and PRO (5, 
10 and 15 µg/ml). The result was reported in terms of 
relative standard deviation (% RSD). 
Accuracy (recovery study) 
The  accuracy  of  the  method  was  determined  by 
calculating recovery of DZP and PRO by the standard 
addition method. Known amounts of standard solutions 
of DZP and PRO were added at 50, 75 and 100 % level 
to prequantified sample  solutions of DZP and PRO (3 
µg/ml for DZP and 15 µg/ml for PRO). The amounts of 
DZP  and  PRO  were  estimated  by  applying  obtained 
values  to the  respective  regression  line  equations.  The 
experiment was repeated for five times. 
Limit of detection and Limit of quantification  
The  limit  of  detection  (LOD)  and  the  limit  of 
quantification  (LOQ)  of  the  drug  were  derived  by 
calculating  the  signal-to-noise  ratio  (S/N,  i.e.,  3.3  for 
LOD  and  10  for  LOQ)  using  the  following  equations 
designated  by  International  Conference  on 
Harmonization (ICH) guidelines
30. 
LOD = 3.3 × σ/S 
LOQ = 10 × σ/S 
Where, σ = the standard deviation of the response and S 
= slope of the calibration curve. 
Analysis of DZP and PRO in combined tablet dosage 
form  
Twenty  Tablets  were  weighed  and  powdered.  The 
powder equivalent to 2 mg of DZP and 10 mg of PRO 
was transferred to a 100 ml volumetric flask. Methanolic 
sulphuric acid (50 ml) was added to it and sonicated for 
20 min. The solution was filtered through Whatman filter 
paper  No.  41  and  the  volume  was  adjusted  up  to  the 
mark  with  methanolic  sulphuric  acid.  This  solution  is 
expected to contain 100 µg/ml of DZP and 100 µg/ml of 
PRO.  This  solution  (1.5  ml)  was  taken  in  to  a  10  ml 
volumetric flask and the volume was adjusted up to mark 
with  methanolic  sulphuric  acid  to  get  a  final 
concentration of DZP (3 µg/ml) and PRO (15  µg/ml). 
The responses of the sample solution were measured at 
248 nm and 242 nm for quantitation of DZP and PRO, 
respectively. The amounts of the DZP and PRO present 
in  the  sample  solution  were  calculated  by  fitting  the 
responses into the regression equation for DZP and PRO 
in the proposed method. Patel Satish A et al. IRJP 2 (8) 2011 119-123 
IRJP 2 (8) August 2011          Page 119-123 
 
RESULTS AND DISCUSSION 
The standard solutions of DZP and PRO were scanned 
separately  in  the  UV  range,  and  zero-order  spectra 
(Figure  1)  thus  obtained  was  then  processed  to  obtain 
first-derivative spectra. Data were recorded at an interval 
of 2 nm. The two derivative spectra showed maximum 
absorbance at 248 nm (ZCP of PRO) for DZP and 242 
nm (ZCP of DZP) for PRO. First-derivative absorbances 
(D1) were recorded 248 nm  for DZP and 242  nm  for 
PRO  (Figure  2).  First  derivative  spectra  give  good 
quantitative  determination  of  both  the  drugs  at  their 
respective without any interference from the other drug 
in  their  combined  dosage  formulations.  Second  and 
third-ordered  derivative  spectra  of  the  drugs  were  not 
tested  because  the  first-order  spectra  give  satisfactory 
ZCPs  and  good  quantitative  determination  of  both  the 
drugs without any interference. 
Linear  correlation  was  obtained  between  absorbances 
and concentrations of DZP and PRO in the concentration 
ranges of 2.5–30 µg/ml for both drug. The linearity of 
the calibration curve was validated by the high values of 
correlation coefficient of regression (Table 1). The RSD 
values  for  DZP  and  PRO  were  found  to  be  1.59  and 
1.44%, respectively (Table 1). The low values of relative 
standard  deviation  (less  than  2  %)  indicate  that  the 
proposed method is repeatable. The low RSD values of 
interday (0.84 – 1.96 and 1.20 – 1.98 %)) and intraday 
(0.54–1.72  and  0.57–1.65  %)  for  DZP  and  PRO, 
respectively, reveal that the proposed method is precise 
(Table 1). LOD values for DZP and PRO were found to 
be 0.45 and 0.63 µg/ml, respectively and LOQ values for 
DZP and PRO were found to be 1.49 and 2.08 µg/ml, 
respectively  (Table  1).  These  data  show that  proposed 
method  is  sensitive  for  the  determination  of  DZP  and 
PRO. 
The recovery experiment was performed by the standard 
addition method. The mean recoveries were 99.77 ± 1.39 
and  100.6  ±  1.18  %  for  DZP  and  PRO,  respectively 
(Table 2). The results of recovery studies indicate that 
the proposed method is accurate. The proposed validated 
method was successfully applied to determine DZP and 
PRO  in  their  combined  dosage  form.  The  results 
obtained  for DZP and PRO were comparable with the 
corresponding  labeled  amounts  (Table  3).  No 
interference  of  the  excipients  with  the  absorbance  of 
interest  appeared;  hence  the  proposed  method  is 
applicable  for  the  routine  simultaneous  estimation  of 
DZP and PRO in pharmaceutical dosage forms.  
CONCLUSION 
Based  on  the  results,  obtained  from  the  analysis  of 
described method, it can be concluded that the method 
has linear response in the range of 2.5-30 μg/ml for both 
DZP  and  PRO  with  co-efficient  of  correlation,  (r
2)  = 
0.9978 and (r
2) = 0.9980 for DZP and PRO, respectively. 
The result of the analysis of pharmaceutical formulation 
by  the  proposed  method  is  highly  reproducible  and 
reliable and it is in good agreement with the label claim 
of  the  drug.  The  additives  usually  present  in  the 
pharmaceutical  formulation  of  the  assayed  sample  did 
not interfere with determination of DZP and PRO. The 
method can be used for the routine analysis of the DZP 
and  PRO  in  combined  dosage  form  without  any 
interference of excipients. 
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TABLE 1: REGRESSION ANALYSIS DATA AND SUMMARY OF VALIDATION PARAMETERS FOR THE PROPOSED METHOD 
 
PARAMETERS  First-derivative UV Spectrophotometry 
DZP at 248 nm  PRO at 242 nm 
Concentration range (µg/ml)  2.5 - 30  2.5 - 30 
Regression equation (y = a + bc) 
Slope (b) 
Intercept (a) 
y = 0.0045x + 0.0051 
0.0045 
0.0051 
y = 0.0047x + 0.0031 
0.0047 
0.0031 
Correlation Coefficient (r
2)  0.9978  0.9980 
Accuracy (% 
recovery) 
(n = 5) 
Level I  98.65 ± 1.68  100.3 ± 1.35 
Level II  101.2 ± 1.84  99.65 ± 1.22 
Level III  99.45 ± 0.64  101.8 ± 0.98 
Repeatability (%RSD
a, n = 6),  1.59  1.44 
Interday (n = 3) (%RSD)  0.84 – 1.96  1.20 – 1.98 
Intraday(n = 3) (%RSD)  0.54 – 1.72  0.57 – 1.65 
LOD
b (µg/ml)  0.45  0.63 
LOQ
c (µg/ml)  1.49  2.08 
aRSD = Relative standard deviation. 
bLOD = Limit of detection. 
cLOQ = Limit of quantification 
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TABLE 2: RECOVERY DATA OF PROPOSED METHOD 
Drug  Level  Amount taken 
(µg/ml) 
Amount added 
(µg/ml) 
Amount found 
(µg/ml) 
% Mean recovery ± S.D. 
(n = 5) 
 
DZP 
 
I  3  1.5  4.44  98.65 ± 1.68 
II  3  2.25  5.31  101.2 ± 1.84 
III  3  3  5.97  99.45 ± 0.64 
 
PRO 
I  15  7.5  22.57  100.3 ± 1.35 
II  15  11.25  26.16  99.65 ± 1.22 
III  15  15  30.54  101.8 ± 0.98 
S. D. is Standard deviation and n is number of determinations 
 
TABLE 3: ANALYSIS OF PRO AND DZP BY PROPOSED METHOD 
Tablet 
 
Label claim (mg)  Amount found (mg)  % Label claim ± S. D. 
(n = 3) 
DZP  PRO  DZP  PRO)  DZP  PRO 
I 
2  10  2.00  10.06 
100.3 ± 0.93  100.6 ± 1.11 
II  2  10  1.97  9.93  98.25 ± 1.32  99.32 ± 1.65 
S. D. is Standard deviation and n is number of determinations 
 
 
FIGURE 1: Overlain zero-order absorption spectra of DZP and PRO 
 
 
 
FIGURE 2: Overlain first-order derivative spectra of DZP and PRO 
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